The diagnostic value of magnetic resonance imaging guided fusion contrast-enhanced ultrasound to detect prostate cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064793

Enrollment

Unknown

Registered

2022-10-18

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Gold Standard:biopsy pathological results

Index test:contrast-enhanced ultrasound combined with biparametric magnetic resonance imaging to detect prostate cancer

Eligibility

Sex/Gender

Male

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. PSA>10ng/ml, regardless of fPSA/PSA or PSAD abnormalities; 2. Abnormal rectal digital examination; 3. PSA4-10ng/ml, combined with fPSA/PSA or PSAD abnormalities; 4. Complete multi parameter magnetic resonance imaging before surgery, with a PI-RADS score of 3-5 points; 5. Male patient, aged 18-80 years old.

Exclusion criteria

Exclusion criteria: 1.PSA>100ng/ml; 2. PI-RADS score of 5 and the lesion is diffuse, with or without metastasis; 3. After radiotherapy for prostate cancer; 4. Endocrine therapy before prostate cancer puncture; 5. Sulfur hexafluoride contrast agent is allergic and cannot undergo ultrasound contrast examination.

Design outcomes

Primary

Measure	Time frame
sensitivity;specifity;accuracy;area under the receiver operating characteristic curve;	—

Secondary

Measure	Time frame
Qualitative and quantitative contrast-enhanced ultrasound characteristics of prostate cancer;	—

Countries

China

Contacts

Public ContactXiang Lihua

Shanghai Tenth People's Hospital

xianglihua1121@163.com+86 18817366922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026